Over the past 25 years, TROG Cancer Research has recorded 220 publications in national and international journals. View our current list of publications below.
| Month/Year published | TROG Number | Acronym | Tumour | Citation | Category | Journal |
|---|---|---|---|---|---|---|
| 13/09/2024 | 8.08 | TOPGEAR | Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. N Engl J Med. 2024 Sep 14. doi: 10.1056/NEJMoa2405195. Epub ahead of print. PMID: 39282905. | A | New England Journal of Medicine | |
| 08/07/2024 | 21.07 | SOCRATES | Wigg, A., Tibballs, J., Woodman, R. et al. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). BMC Cancer 24, 813 (2024). https://doi.org/10.1186/s12885-024-12504-2 | A | BMC Cancer | |
| 05/07/2024 | 17.02 | OUTRUN | CNS | Robledo KP, Lefresne S, Soon YY, Sahgal A, Pinkham MB, Nichol A, Soo RA, Parmar A, Hegi-Johnson F, Doherty M, Solomon BJ, Shultz DB, Tham IW, Sacher AG, Tey J, Leong CN, Koh WY, Huang Y, Ang YLE, Low J, Yong C, Lim MC, Tan AP, Lee CK, Ho C. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. BMJ Open. 2024 Jul 5;14(7):e078335. doi: 10.1136/bmjopen-2023-078335. PMID: 38969367. | A | BMJ open |
| 25/03/2024 | 15.03 | FASTRACK II | Genitourinary | Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. PMID: 38423047. | A | Lancet Oncology |
| 11/03/2024 | 18.06 | FIG | CNS | Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. [18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. PMID: 38585372; PMCID: PMC10998205. | A | Physics and Imaging in Radiation Oncology |
| 06/03/2024 | 12.02 | PET-LAB | Breast | PET Scans for Locally Advanced Breast Cancer and Diagnostic MRI to determine the extent of operation and Radiotherapy (PET LABRADOR) TROG 12.02. doi:10.31488/bjcr.190 | A | British Journal of Cancer Research |
| 05/02/2024 | 16.02 | Local HER-O | Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02). Breast. 2024 Feb 5;74:103675. doi: 10.1016/j.breast.2024.103675. Epub ahead of print. PMID: 38340685. | A | The Breast | |
| 01/01/2024 | 18.06 | FIG | Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. PMID: 38181810. | A | The Lancet Oncology | |
| 25/12/2023 | 21.12 | ASPIRE | Khong J, Tee H, Gorayski P, Le H, Penniment M, Jessop S, Hansford J, Penfold M, Green J, Skelton K, Saran F. Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research. J Med Imaging Radiat Oncol. 2023 Dec 25. doi: 10.1111/1754-9485.13614. Epub ahead of print. PMID: 38146017. | B | Journal Of Medical Imaging And Radiation Oncology | |
| 21/11/2023 | 17.03 | LARK | Liver | Sengupta C, Nguyen DT, Moodie T, Mason D, Luo J, Causer T, Liu SF, Brown E, Inskip L, Hazem M, Chao M, Wang T, Lee YY, van Gysen K, Sullivan E, Cosgriff E, Ramachandran P, Poulsen P, Booth J, O'Brien R, Greer P, Keall P. The first clinical implementation of real-time 6 degree-of-freedom image-guided radiotherapy for liver SABR patients. Radiother Oncol. 2023 Nov 24;190:110031. doi: 10.1016/j.radonc.2023.110031. Epub ahead of print. PMID: 38008417. | A | Radiotherapy and Oncology |
| 21/10/2023 | 13.01 | SAFRON II | Lung | Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II). Int J Radiat Oncol Biol Phys. 2023 Oct 21:S0360-3016(23)08005-7. doi: 10.1016/j.ijrobp.2023.09.052. Epub ahead of print. PMID: 37871885. | A | International Journal of Radiation Oncology, Biology, Physics |
| 04/10/2023 | 3.04 | RADAR | Ong, W. L., Nikitas, J., Joseph, D., Steigler, A., Millar, J., Valle, L., . . . Kishan, A. U. (2023). Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. International Journal of Radiation Oncology Biology Physics. doi:10.1016/j.ijrobp.2023.09.051 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/10/2023 | 3.04 | RADAR | Ong, W. L., Nikitas, J., Joseph, D. J., Steigler, A., Denham, J. W., Millar, J. L., . . . Kishan, A. U. (2023). Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR).. Int J Radiat Oncol Biol Phys, 117(2S), S93-S94. doi:10.1016/j.ijrobp.2023.06.424 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 11/08/2023 | 18.06 | FIG | CNS | (EDITORIAL) Barry N, Francis RJ, Ebert MA, Koh ES, Rowshanfarzad P, Hassan GM, Kendrick J, Gan HK, Lee ST, Lau E, Moffat BA, Fitt G, Moore A, Thomas P, Pattison DA, Akhurst T, Alipour R, Thomas EL, Hsiao E, Schembri GP, Lin P, Ly T, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Bailey D, Cook O, Whitehead A, Dykyj R, Rossi A, Grose A, Scott AM. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. Eur J Nucl Med Mol Imaging. 2023 Aug 11. doi: 10.1007/s00259-023-06371-5. Epub ahead of print. PMID: 37563351. | A | European Journal of Nuclear Medicine and Molecular Imaging |
| 04/08/2023 | 18.06 | FIG | CNS | Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, Lau E, Khasraw M, Nowak AK, Bailey DL, Moffat BA, Fitt G, Hicks RJ, Coffey R, Verhaak R, Walsh KM, Barnes EH, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas PA, Roach P, Back M, Leonard R, Scott AM. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. BMJ Open. 2023 Aug 4;13(8):e071327. doi: 10.1136/bmjopen-2022-071327. PMID: 37541751; PMCID: PMC10407346. | A | BMJ Open |
| 04/08/2023 | 18.06 | FIG | CNS | Langen KJ, Galldiks N, Lohmann P, Mottaghy FM. Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3817-3819. doi: 10.1007/s00259-023-06426-7. PMID: 37682302; PMCID: PMC10611633. | A | European Journal of Nuclear Medicine and Molecular Imaging |
| 03/08/2023 | 6.01 | LGG | Central Nervous System | Kros JM, Rushing E, Uwimana AL, Hernández-Laín A, Michotte A, Al-Hussaini M, Bielle F, Mawrin C, Marucci G, Tesileanu CMS, Stupp R, Baumert B, van den Bent M, French PJ, Gorlia T. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Neuro Oncol. 2023 Aug 3;25(8):1443-1449. doi: 10.1093/neuonc/noac282. PMID: 36571817; PMCID: PMC10398806. | B | Neuro Oncology |
| 18/07/2023 | ` | ` | Nguyen H, Montgomery R, Sundaresan P. Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials. J Med Imaging Radiat Oncol. 2023 Jul 16. doi: 10.1111/1754-9485.13564. Epub ahead of print. PMID: 37454368. | ` | International Journal of Radiation Oncology, Biology, Physics | |
| 09/05/2023 | 14.02 | RAIDER | GU | Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, Choudhury A, Foroudi F, Gribble H, Henry A, Hilman S, Hindson B, Lewis R, Muthukumar D, McLaren DB, McNair H, Nikapota A, Olorunfemi A, Parikh O, Philipps L, Rimmer Y, Syndikus I, Tolentino A, Varughese M, Vassallo-Bonner C, Webster A, Griffin C, Hall E. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clin Oncol (R Coll Radiol). 2023 Sep;35(9):586-597. doi: 10.1016/j.clon.2023.05.002. Epub 2023 May 9. PMID: 37225552. | A | Clinical Oncology |
| 21/04/2023 | 9.02 | CHISEL | Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. PMID: 37087060. | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/12/2022 | 13.01 | SAFRON II | Lung | Lourenco RA, Khoo T, Crothers A, Haas M, Montgomery R, Ball D, Bressel M, Siva S. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):968-976. doi: 10.1016/j.ijrobp.2022.01.024. Epub 2022 May 27. PMID: 36395809. | A | International Journal of Radiation Oncology, Biology, Physics |
| 01/11/2022 | 18.06 | FIG | CNS | Koh ES, Francis RJ, Ebert M, Gan H, Lee ST, Lau E, Moore A, Grose A, Rossi A, Ng SP, Yap J, Ly T, Lin P, Pinkham MB, Ngai S, Yu C, Gorayski P, Le H, Kirkwood ID, Vallat W, Syed F, Krishna D, Khan S, Gill S, Thomas E, Back M, Barnes EH, Moffat BA, Scott F, Adda L, Foroudi F, Lourenco RDA, Nowak AK, Bailey DL, Scott AM. NIMG-49. A PROSPECTIVE, MULTI-CENTRE TRIAL OF FET-PET IN GLIOBLASTOMA PATIENTS - THE TROG 18.06 FIG STUDY: KEY ASPECTS OF IMAGING AND RADIATION ONCOLOGY CREDENTIALING. Neuro Oncol. 2021 Nov 12;23(Suppl 6):vi140. doi: 10.1093/neuonc/noab196.547. PMCID: PMC8598843. | A | Neuro Oncology Open Access |
| 06/08/2022 | 7.01 | DCIS | Breast | Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. PMID: 35934006. | A | The Lancet |
| 02/08/2022 | 12.01 | HPV OROPHARYNX | Head and Neck | McDowell L, Rischin PD, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Fua T, Lin C, Liu C, Corry J. Patient- and clinician-reported outcomes in human papillomavirus-associated tonsillar carcinoma treated with unilateral and bilateral intensity-modulated radiotherapy - a substudy from TROG12.01. Int J Radiat Oncol Biol Phys. 2022 Aug 9:S0360-3016(22)03089-9. doi: 10.1016/j.ijrobp.2022.08.006. Epub ahead of print. PMID: 35961477. | A | Red Journal |
| 11/07/2022 | 3.04 | RADAR | Ma, T. M., Chu, F. I., Sandler, H., Feng, F. Y., Efstathiou, J. A., Jones, C. U., . . . Kishan, A. U. (2022). Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). European Urology, 82(5), 487-498. doi:10.1016/j.eururo.2022.07.011 | A | European Urology | |
| 03/07/2022 | 3.04 | RADAR | Kishan, A. U., Wang, X., Sun, Y., Romero, T., Michalski, J. M., Ma, T. M., . . . Spratt, D. E. (2022). High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. European Urology, 82(1), 106-114. doi:10.1016/j.eururo.2022.04.003 | A | European Urology | |
| 17/06/2022 | Lehmann J, Hussein M, Barry M, Siva S, Moore A, Chu M, Diez P, Eaton D J, Harwood J, Lonski P, Mackonis E C, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen T S, Subramanian B, Greer P B, Clark C H. A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. Radiotherapy and Oncology. 2022 April; 171 (5). DOI:10.1016/j.radonc.2022.04.019 | na | Radiotherapy and Oncology | |||
| 16/06/2022 | 14.04 | HART | Breast | Kron T, Bressel M, Lonski P, Hill C, Mercieca-Bebber R, Ahern V, Lehman M, Johnson C, Latty D, Ward R, Miller D, Banjade D, Morriss D, De Abreu Lourenco R, Woodcock J, Montgomery R, Lehmann J, Chua BH. TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients. Clin Oncol (R Coll Radiol). 2022 Sep;34(9):e410-e419. doi: 10.1016/j.clon.2022.05.020. Epub 2022 Jun 16. PMID: 35717318. | A | Clinical Oncology |
| 13/05/2022 | 8.03 | RAVES | Genitourinary | van Gysen K, Kneebone A, Le A, Wu K, Haworth A, Bromley R, Hruby G, O'Toole J, Booth J, Brown C, Pearse M, Sidhom M, Wiltshire K, Tang C, Eade T. Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. Phys Imaging Radiat Oncol. 2022 May 13;22:91-97. doi: 10.1016/j.phro.2022.05.004. PMID: 35602546; PMCID: PMC9117914. | A | Physics and Imaging in Radiation Oncology |
| 04/05/2022 | 12.01 | HPV OROPHARYNX | oropharyngeal | Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ; Trans-Tasman Radiation Oncology Group and the De-ESCALaTE HPV Trial Group. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Ann Oncol. 2022 Aug;33(8):804-813. doi: 10.1016/j.annonc.2022.04.074. Epub 2022 May 4. PMID: 35525376. | A | Annals of Oncology |
| 04/04/2022 | 3.04 | RADAR | Delahunt, B., Steigler, A., Atkinson, C., Christie, D., Duchesne, G., Egevad, L., . . . Denham, J. W. (2022). Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology, 54(1), 49-54. doi:10.1016/j.pathol.2021.11.004 | A | Pathology | |
| 03/03/2022 | Chang D, Moore A, van Dyk S, Khaw P. Why Quality Assurance is Necessary in Gynecologic Radiation Oncology. Int J Gynecol Cancer. 2022 Mar;32(3):402-406. doi: 10.1136/ijgc-2021-002534. | na | International Journal of Gynecological Cancer | |||
| 01/03/2022 | 12.01 | HPV OROPHARYNX | Head and Neck | McDowell L, Bressel M, King MT, Corry J, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Rischin D. Patient-report symptom severity, health-related quality of life and emotional distress trajectories during and after radiotherapy for HPV-associated oropharyngeal cancer: a XXXX.XXXX secondary analysis. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00199-2. doi: 10.1016/j.ijrobp.2023.02.041. Epub ahead of print. PMID: 36868523. | A | International Journal of Radiation Oncology, Biology, Physics |
| 09/02/2022 | 14.02 | RAIDER | GU | Webster A, McNair HA, Hansen VN, Lewis R, Patel E, Miles E, Hall E, Hafeez S, Huddart R; RAIDER, HYBRID Trial Management Groups. Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. Tech Innov Patient Support Radiat Oncol. 2022 Feb 9;21:31-35. doi: 10.1016/j.tipsro.2022.01.002. PMID: 35198744; PMCID: PMC8841376. | B | Technical Innovations & Patient Support in Radiation Oncology |
| 09/02/2022 | 14.02 | RAIDER | GU | Webster A, McNair HA, Hansen VN, Lewis R, Patel E, Miles E, Hall E, Hafeez S, Huddart R; RAIDER, HYBRID Trial Management Groups. Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. Tech Innov Patient Support Radiat Oncol. 2022 Feb 9;21:31-35. doi: 10.1016/j.tipsro.2022.01.002. PMID: 35198744; PMCID: PMC8841376. | A | Technical Innovations & Patient Support in Radiation Oncology |
| 01/02/2022 | 8.04 | PORTEC-3 | Gynaecologic | Wortman BG, Post CCB, Powell ME, Khaw P, Fyles A, D'Amico R, Haie-Meder C, Jürgenliemk-Schulz IM, McCormack M, Do V, Katsaros D, Bessette P, Baron MH, Nout RA, Whitmarsh K, Mileshkin L, Lutgens LCHW, Kitchener HC, Brooks S, Nijman HW, Astreinidou E, Putter H, Creutzberg CL, de Boer SM. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):390-399. doi: 10.1016/j.ijrobp.2021.09.042. Epub 2021 Oct 2. PMID: 34610387. | C | International Journal of Radiation Oncology, Biology, Physics |
| 20/01/2022 | Multi | GU | Kishan AU, Steigler A, Denham JW, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022;8(3):e216871. doi:10.1001/jamaoncol.2021.6871 | NA | JAMA Oncology | |
| 20/01/2022 | 3.04 | RADAR | Kishan, A. U., Steigler, A., Denham, J. W., Zapatero, A., Guerrero, A., Joseph, D., . . . Romero, T. (2022). Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncology, 8(3). doi:10.1001/jamaoncol.2021.6871 | A | JAMA Oncology | |
| 17/01/2022 | 3.04 | RADAR | Kishan, A. U., Sun, Y., Hartman, H., Pisansky, T. M., Bolla, M., Neven, A., . . . Spratt, D. E. (2022). Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. The Lancet Oncology, 23(2), 304-316. doi:10.1016/S1470-2045(21)00705-1 | A | The Lancet Oncology | |
| 10/01/2022 | Multi | GU | Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb;23(2):304-316. doi: 10.1016/S1470-2045(21)00705-1. Epub 2022 Jan 17. PMID: 35051385. | NA | Lancet Oncology | |
| 11/12/2021 | 8.04 | PORTEC-3 | Gynaecologic | Khaw P, Do V, Lim K, Cunninghame J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. Clin Oncol (R Coll Radiol). 2022 Mar;34(3):198-204. doi: 10.1016/j.clon.2021.11.015. Epub 2021 Dec 11. PMID: 34903431. | C | Clinical Oncology |
| 15/11/2021 | 12.01 | HPV OROPHARYNX | oropharyngeal | Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Herschtal A, Fisher R, Fua T, Lin C, Liu C, Hughes BGM, McGrath M, McDowell L, Corry J. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):876-886. doi: 10.1016/j.ijrobp.2021.04.015. Epub 2021 Jun 4. PMID: 34098030. | A | International Journal of Radiation Oncology, Biology, Physics |
| 01/11/2021 | 3.04 | RADAR | Kishan, A. U., Sun, Y., Pisansky, T. M., Bolla, M., Steigler, A., Denham, J. W., . . . Spratt, D. E. (2021). Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer. International journal of radiation oncology, biology, physics, 111(3). doi:10.1016/j.ijrobp.2021.07.046 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/11/2021 | 3.04 | RADAR | Kishan, A. U., Romero, T., Wang, X., Pisansky, T. M., Roach, M., Bolla, M., . . . Spratt, D. E. (2021). Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials. International journal of radiation oncology, biology, physics, 111(3), S78-S79. doi:10.1016/j.ijrobp.2021.07.190 | A | International Journal of Radiation Oncology, Biology, Physics | |
| 01/10/2021 | 13.01 | SAFRON II | Lung | Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145. | A | JAMA |
| 29/08/2021 | 13.01 | SAFRON II | Lung | Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. Published online August 29, 2021. doi:10.1001/jamaoncol.2021.2939 | A | JAMA Oncology |
| 19/08/2021 | 18.04 | MASTERPLAN | Pancreas | Oar, Andrew et al. “AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.” BMC cancer vol. 21,1 936. 19 Aug. 2021, doi:10.1186/s12885-021-08666-y | C | BMC Cancer |
| 01/08/2021 | 15.03 | FASTRACK II | Genitourinary | Hardcastle N, Cook O, Ray X, Moore A, Moore KL, Pryor D, Rossi A, Foroudi F, Kron T, Siva S. Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. Radiat Oncol. 2021 Aug 3;16(1):142. doi: 10.1186/s13014-021-01820-7. PMID: 34344402; PMCID: PMC8330099. | A | Radiation Oncology |
| 01/08/2021 | 07.01/11.03 | PROM | Genitourinary | Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, Chan AW, Basch E, Bell J, Bennett A, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck AC, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis B, Martin L, Mitchell S, Morel T, Nelson L, Norquist J, O'Connor D, Palmer M, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105. PMID: 34193486; PMCID: PMC8246371. | A | BMJ open |
| 11/07/2021 | 11.03 | P_LUNG GP | Lung | Lehman M, Bernard A, See A, King M, Michael M. A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms due to Intrathoracic Disease Who are Not Suitable for Radical Chemo-radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial. Pract Radiat Oncol. 2021 Jul-Aug;11(4):252-263. doi: 10.1016/j.prro.2020.11.009. Epub 2020 Nov 30. PMID: 33271352. | A | Practical Radiation Oncology |
| 11/06/2021 | 17.06 | SC24 | Central Nervous System | Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. Epub 2021 Jun 11. PMID: 34126044. | B | Lancet |
| 06/06/2021 | GHG | NA | Lehman J. Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency | NA | Journal of Radiation Oncology | |
| 05/05/2021 | 6.01 | LGG | Central Nervous System | Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, Tzuk-Shina T, Lucas A, Freixa SV, Golfinopoulos V, Gorlia T, Hottinger AF, Stupp R, Baumert BG. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. Neuro Oncol. 2021 May 5;23(5):803-811. doi: 10.1093/neuonc/noaa252. PMID: 33130890; PMCID: PMC8099470. | B | Neuro Oncology |
| 01/05/2021 | 5.02 | MGMZL | Gastrointestinal | MacManus MP, Roos D, O'Brien P, Capp A, Wirth A, Tsang R, Bressel M, Lade S, Seymour JF. Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. Eur J Cancer. 2021 Jun 4;152:129-138. | A | European Journal of Cancer |
| 01/04/2021 | 17.03 | LARK | Liver | Lee, Y.Y.D., Nguyen, D.T., Moodie, T. et al. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. BMC Cancer 21, 494 (2021). | A | BMC Cancer |
| 01/03/2021 | 8.04 | PORTEC-3 | Gynaecologic | Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger N(P)B, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, Jürgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Smit VTHBM, Putter H, Creutzberg CL. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial. Int J Radiat Oncol Biol Phys. 2021 Mar; 109(4):975-86. | C | International Journal of Radiation Oncology Biology Physics |
| 09/02/2021 | 14.02 | RAIDER | GU | Webster A, Hafeez S, Lewis R, Griffins C, Warren-Oseni K, Patel E, Hansen VN, Hall E, Huddart R, Miles E, McNair HA. The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance. Clin Oncol (R Coll Radiol). 2021 Jul;33(7):461-467. doi: 10.1016/j.clon.2021.02.009. Epub 2021 Mar 23. PMID: 33766503. | B | Clinical Oncology |
| 01/02/2021 | 9.01 | PROARCT | Gastrointestinal | Ng SP, Chu J, Chander S, Bressel M, McKendrick J, Wong R, Steel M, Murray WK, Leong T, Heriot A, Michael M, Ngan SY. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiother Oncol. 2021 Feb; 155:27-32. | A | Radiotherapy and Oncology |
| 01/01/2021 | 14.03 | EORTC 1219 | Nijhuis H, van Rooij W, Gregoire V, Overgaard J, Slotman BJ, Verbakel WF, Dahele M. Investigating the potential of deep learning for patient-specific quality assurance of salivary gland contours using EORTC-1219-DAHANCA-29 clinical trial data. Acta Oncol. 2021 May;60(5):575-581. doi: 10.1080/0284186X.2020.1863463. Epub 2021 Jan 11. PMID: 33427555. | B | Acta Oncologica | |
| 01/01/2021 | 96.01 | - | Genitourinary | Kumar M, Steigler A and Denham JW. The value of combined androgen blockade in the neo-adjuvant treatment of localised prostate cancer – the jury must remain out. (Letter to the Editor) J Clin Oncol. 2010 Sep; 28(25):e445-46. | A | Journal of Clinical Oncology |
| 01/12/2020 | 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1304-1318. doi: 10.1016/j.ijrobp.2020.07.030. Epub 2020 Jul 30. PMID: 32739320. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2020 | 12.01 | HPV OROPHARYNX | Head and Neck | Young R, Solomon B, Corry J, Angel C, Kenny L, Porceddu S, Wratten C, Macann A, Jackson J, Herschtal A, Rischin D. Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial – A Trans-Tasman Radiation Oncology Group study. Oral Oncol. 2020 Nov; 110:104988. | A | Oral Oncology |
| 01/10/2020 | 8.03 | RAVES | Prostate | Kneebone A, Fraser-Browne C, Duchesne G, Fisher R, Frydenberg M, Herschtal A, Williams S, Delprado W, Haworth A, Joseph D, Martin J, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Wiltshire K, Woo H, Davis I, Lim T, Pearse M. A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP "RAVES" Trial. Lancet Oncol. 2020 Oct; 21:1331-40. | A | Lancet Oncology |
| 01/10/2020 | 15.01 | SPARK | Genitourinary | Hewson E, Nguyen D, O'Brien R, Poulsen P, Booth J, Greer P, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Hardcastle N, Siva S, Tai K, Keall P. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Radiother Oncol. 2020 Oct; 151: P234-41. | C | Radiotherapy and Oncology |
| 01/10/2020 | 8.03 | RAVES | Prostate | Vale C, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes M, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar M, Tierney J, for the ARTISITC Meta-analysis Group. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020 Oct; 396(10260):P1422-31. | A | The Lancet |
| 01/09/2020 | 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-wise analysis of 3 randomised phase 3 trials. Radioth Oncol. 2020 Sep; 150: 281-92. | A | Radiotherapy and Oncology |
| 01/09/2020 | 3.04 | RADAR | Pancreas | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. Radiother Oncol. 2020 Sep;150:281-292. doi: 10.1016/j.radonc.2020.07.048. Epub 2020 Jul 31. PMID: 32745667. | A | Radiotherapy on Oncology |
| 01/07/2020 | 15.01 | SPARK | Genitourinary | Keall P, Nguyen D, O'Brien R, Hewson E, Ball H, Poulsen P, Booth J, Greer P, Hunter P, Wilton L, Bromley R, Kipritidis J, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Arumugam S, Sidhom M, Hardcastle N, Siva S, Tai K, Gebski V, Martin J. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. Int J Radiat Oncol Biol Phys. 2020 Jul; 107(3):530-8. | C | International Journal of Radiation Oncology Biology Physics |
| 01/07/2020 | 5.01 | POST | Head and Neck | Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, Moore A, Veness M, Yao M, Johansen J, Mehanna H, Rischin D, Le QT. Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN). Int J Radiat Oncol Biol Phys. 2020 Jul; 107(4):641-651. | C | International Journal of Radiation Oncology Biology Physics |
| 01/06/2020 | NA | - | NA | McDowell L, Goode S, Sundaresan P. Adapting to a global pandemic through live virtual delivery of a cancer collaborative trial group conference: The TROG 2020 experience. J Med Imaging Radiat Oncol. 2020 Jun; 64(3):414-21. | NA | Journal of Medical Imaging and Radiation Oncology |
| 01/06/2020 | 18.04 | MASTERPLAN | Pancreas | Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng S, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman K, Chang DT, Kneebone A. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiotherapy (SBRT). Pract Radiat Oncol. 2020 Jun; 10(3):e136-46. | C | Practical Radiation Oncology |
| 01/06/2020 | 3.04 | RADAR | Prostate | Panettieri V, Rancati T, Onjukka E, Ebert MA, Joseph DJ, Denham JW, Steigler A, Millar JL. External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Front Oncol. 2020 Jun;10:910. | A | Frontiers in Oncology |
| 01/05/2020 | 7.01 | DCIS | Breast | King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast conserving therapy for non-low risk ductal carcinoma in situ: two-year results of a randomised controlled trial (BIG 3-07/TROG 07.01). Lancet Oncol. 2020 May; 21(5):685?698. | A | Lancet Oncology |
| 01/04/2020 | NA | - | NA | Hardcastle N, Bignell F, Nelms B, Siva S, Kneebone A, Lao L, Cook O, Harris M, Shakeshaft J. The challenge of planning vertebral body SBRT: Optimising target volume coverage. Med Dosim. 2020 Apr; 45(3):302-7. | NA | Medical Dosimetry |
| 01/04/2020 | 16.01 | NIVORAD | Lung | Hardcastle N, Kron T, Cook O, Lehmann J, Mitchell P, Siva S. Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Phys Med. 2020 Apr; 72:16-21 | C | European Journal of Medical Physics |
| 01/01/2020 | 7.01 | DCIS | Breast | Olivotto I, Link E, Phillips C, Whelan T, Bryant G, Kunkler I, Westenberg A, Purohit K, Ahern V, Graham P, Akra M, McArdle O, Ludbrook J, Harvey J, Maduro J, Kirkove C, Gruber G, Martin J, Campbell I, Delaney G, Chua BH; BIG 03-07/TROG 07.01 trial investigators. International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiother Oncol. 2020 Jan; 142:180-5. | A | Radiotherapy and Oncology |
| 01/12/2019 | 11.02 | SCORAD III | Symptom Management | Hoskin P.J, Hopkins K., Misra V, Holt T, Mcmenemin R, Dubois D, Mckinna F, Foran B, Madhavan K, Macgregor C, Bates A, O'rourke N, Lester J.F, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas S.S, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status among Patients with Spinal Canal Compression from Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA. 2019 Dec; 322(21):2084-94. | B | Journal of the American Medical Association |
| 01/12/2019 | 10.02 | RAPID | Breast | Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72. | B | Lancet |
| 01/11/2019 | 15.01 | SPARK | Genitourinary | Hewson E, Nguyen D, O'Brien R, Kim J, Montanaro T, Moodie T, Greer P, Hardcastle N, Eade T, Kneebone A, Hruby G, Hayden A, Turner S, Siva S, Tai K, Hunter P, Sams J, Poulsen P, Booth J, Martin J, Keall P. The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Med Phys. 2019 Nov; 46(11): 4725-37. | C | Medical Physics |
| 01/11/2019 | 8.05 | WBRT | Skin | Hong A, Fogarty G, Dolven-Jacobsen K, Burmeister B, Lo S, Haydu L, Vardy J, Nowak A, Dhillon H, Ahmed T, Shivalingam B, Long G, Menxies A, Hruby G, Drummond K, Mandel C, Middleton M, Reisse C, Paton E, Steel V, Williams N, Scolyer R, Morton R, Thompson J. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 Nov; 37(33): 3132-41. | C | Journal of Clinical Oncology |
| 01/10/2019 | 6.01 | LGG | Central Nervous System | Jaspers J, Mèndez Romero A, Hoogeman MS, van den Bent M, Wiggenraad RGJ, Taphoorn MJB, Eekers DBP, Lagerwaard FJ, Lucas Calduch AM, Baumert BG, Klein M. Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial. Front Oncol. 2019 Oct 1;9:991. doi: 10.3389/fonc.2019.00991. PMID: 31681562; PMCID: PMC6797857. | B | Frontiers in Oncology |
| 01/07/2019 | 15.01 | SPARK | Genitourinary | Wolf J, Nicholls J, Hunter P, Nguyen D, Keall P, Martin J. Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial. Radiother Oncol. 2019 Jul; 136:143-7. | C | Radiotherapy and Oncology |
| 01/07/2019 | 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Jul; 20(9):1273-85. | C | Lancet Oncology |
| 01/06/2019 | 8.03 | RAVES | Prostate | Cloak K, Jameson M, Paneghel A, Wiltshire K, Kneebone A, Pearse M, Sidhom M, Tang C, Fraser-Browne C, Holloway L, Haworth A. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. J Med Imaging Radiat Oncol. 2019 Jun; 63(3):390-8. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/05/2019 | 6.01 | LGG | Central Nervous System | Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):90-100. doi: 10.1016/j.ijrobp.2019.01.003. Epub 2019 Feb 2. PMID: 30716525. | B | International Journal of Radiation Oncology, Biology and Physics |
| 01/04/2019 | 9.02 | CHISEL | Lung | Ball D, Mai T, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vaneski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Le H. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Apr; 20(4):494-503. | A | Lancet Oncology |
| 01/04/2019 | 3.03 | Lymphoma | Wirth A, Prince H, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone J, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Int J Radiat Oncol Biol Phys. 2019 Apr; 103(5):1158-1166 | C | International Journal of Radiation Oncology Biology Physics | |
| 01/02/2019 | 12.03 | EAT | Head & Neck | Britton B, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. Eating As Treatment (EAT): a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy (TROG 12.03). Int J Radiat Oncol Biol Phys. 2019 Feb; 103(2):353-62. | C | International Journal of Radiation Oncology Biology Physics |
| 01/02/2019 | 3.04 | RADAR | Genitourinary | Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna K, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb; 20(2):267-81. | A | Lancet Oncology |
| 19/10/2018 | 14.03 | EORTC 1219 | Tol JP, Dahele M, Gregoire V, Overgaard J, Slotman BJ, Verbakel WFAR. Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance. Radiother Oncol. 2019 Jan;130:75-81. doi: 10.1016/j.radonc.2018.10.005. Epub 2018 Oct 19. PMID: 30348462. | B | Radiotherapy and Oncology | |
| 10/10/2018 | 2.03 | GU | Gogna NK, Duchesne G, O'Brien P, Spry N, Turner S, Matthews J, Borg M, Bauman K, King M, Burmeister E. Trans Tasman Radiation Oncology Group Cancer Research: Phase III - Muscle Invasive Bladder Cancer trial (TROG 02.03): A moral dilemma. J Med Imaging Radiat Oncol. 2018 Oct;62(5):668-670. doi: 10.1111/1754-9485.12752. PMID: 30288941. | A | Journal of Imaging Radiation Oncology | |
| 01/10/2018 | 99.03 | - | Lymphoma | MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour J. A Randomized Trial of Systemic Therapy after involved-field Radiotherapy in patients with Early Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct; 36(29):2918-25. | A | Journal of Clinical Oncology |
| 01/05/2018 | 6.01 | LGG | Central Nervous System | Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC 22033-26033 clinical trial. Eur J Cancer. 2018 May; 94:168-78. | B | European Journal of Cancer |
| 01/05/2018 | 5.01 | POST | Skin | Porceddu S, Bressel M, Poulsen M, Stoneley A, Veness M, Kenny L, Wratten C, Corry J, Cooper S, Fogarty G, Collins M, Collins M, Macann A, Milross C, Penniment M, Liu H, King M, Panizza B, Rischin D. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. J Clin Oncol. 2018 May; 36(13):1275-83. | A | Journal of Clinical Oncology |
| 01/04/2018 | 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Bulsara M, Kearvell R, Joseph D, Denham J. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. J Med Imag Radiat Oncol. 2018 Apr; 62(2):248-55. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/04/2018 | 15.01 | SPARK | Genitourinary | Keall P, Nguyen D, O'Brien R, Caillet V, Hewson E, Poulsen P, Bromley R, Bell L, Eade T, Kneebone A, Martin J, Booth J. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. Radiother Oncol. 2018 Apr; 127(1):6-11. | C | Radiotherapy and Oncology |
| 01/03/2018 | 9.02 | CHISEL | Lung | Kron T, Chesson B, Hardcastle N, Crain M, Clements N, Burns M, Ball D. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. Br J Radiol. 2018 Mar; 91(1085):20170737. | A | British Journal of Radiology |
| 01/02/2018 | 3.01 | Gastrointestinal | Penniment M, De Ieso P, Harvey J, Stephens S, Au H, O'Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):114-24. | A | Lancet Gastroenterolgy and heptalogy | |
| 01/02/2018 | 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Joseph D, Denham J. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radioth Oncol. 2018 Feb; 126(2):249-56. | A | Radiotherapy and Oncology |
| 01/02/2018 | 9.03 | MP3 | Skin | Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. J Med Imag Radiat Oncol. 2018 Feb; 62(3):412-9. | A | Journal Of Medical Imaging And Radiation Oncology |
| 01/02/2018 | 8.04 | PORTEC-3 | Gynaecologic | de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb; 19(3):295–309. | C | Lancet Oncology |
| 01/01/2018 | TROG | - | Head and Neck | Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan; 126(1):3-24. | NA | Radiotherapy and Oncology |
| 01/12/2017 | 7.03 | DCIS | Head and Neck | Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncol. 2017 Dec; 75:75-80. | A | Oral Oncology |
| 01/11/2017 | 3.04 | RADAR | Genitourinary | Sharpley, C.F., Bitsika, V., Christie, D.R.H., Bradford, R., Steigler, A., & Denham, J.W. Total Depression and Subtypes in Prostate Cancer Survivors 10 years after treatment. Eur J Cancer Care. 2017 Nov; 26(6):e12630 | A | European Journal of Cancer Care |
| 01/10/2017 | 8.03 | RAVES | Genitourinary | Sundaresan P, Ager B, Turner S, Costa D, Kneebone A, Pearse M, et al. A randomised controlled trial evaluating the utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related decision-making. Radiother Oncol. 2017 Oct; 125(1): 124-29. | A | Radiotherapy and Oncology |
| 01/09/2017 | 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, King M, Bowe S, Stockler M, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017 Sep; 18(9):1192-1201 | C | Lancet Oncology |
| 01/08/2017 | 8.08 | WBRT | Gastrointestinal | Leong T, Smithers M, Haustermans K, Michael M, Gebski V, Miller D, Simes J, Zalcberg J, Boussioutas A, Findlay M, O'Connell R, Verghis J, Willis D, Kron T, Crain M, Murray W, Lordick F, Swallow C, Darling G, Wong R. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG (formerly NCIC CTG). Ann Surg Oncol. 2017 Aug; 24(8): 2252-58 | C | Annals of Surgical Oncology |
| 01/07/2017 | 7.04 | - | Head and Neck | Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4):948-54 | A | International Journal of Radiation Oncology Biology Physics |
| 01/07/2017 | 99.05 | - | Lung | Cox A, Akhurst T, Bressel M, MacManus M, Ball D. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy. Radiother and Oncol. 2017 Jul; 124(1):25-30 | A | Radiotherapy and Oncology |
| 01/07/2017 | 15.01 | SPARK | Genitourinary | Legge K, Greer P, Keall P, Booth J, Arumugam S, Moodie T, Nguyen D, Martin J, O'Connor D, Lehmann J. Technical Note: TROG 15.01 SPARK Trial Multi-Institutional Imaging Dose Measurement. J Appl Clin Med Phys. 2017 Jul; 18(5):358-63 | C | Journal of Applied Clinical Medical Physics |
| 01/06/2017 | 8.01 | PROFIT | Genitourinary | Catton C, Lukka H, Gu C, Martin J, Supiot S, Chung P, Bauman G, Bahary J, Ahmed S, Cheung P, Tai KH, Wu J, Parliament M, Tsakiridis T, Corbett T, Tang C, Days I, Warde P, Craig T, Julian J, Levine M. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun; 35(17):1884-90 | B | Journal of Clinical Oncology |
| 01/04/2017 | 3.04 | RADAR | Genitourinary | Bitska V, Sharpley CF, Bradford R, Steigler A, Denham JW. Measuring Personal and Functional Changes in Prostate Cancer Survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial. Psycho-Oncology. 2017 Apr; 26(4):553-55 | A | Pyscho Oncology |
| 01/04/2017 | 15.01 | SPARK | Genitourinary | Ngyuen D, O'Brien R, Kim J, Huang C, Booth J, Wilton L, Greer P, Legge K, Poulsen P, Martin J, Keall P. The First Clinical Implementation of a Real-Time Six Degree Of Freedom Tracking System For Intrafaction Prostate Motion During Radiation Therapy. Radiother and Oncol. 2017 Apr; 123(1):37-42 | C | Radiotherapy and Oncology |
| 01/03/2017 | 2.02 | - | Head and Neck | Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar; 97(4): 678-86 | A | International Journal of Radiation Oncology Biology Physics |
| 01/03/2017 | 8.02 | GBM | Central Nervous System | Perry J, Laperriere N, O'Callaghan C, Brandes A, Menten J, Phillips C, Fay m, Nishikava R, Carncross J, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Goldinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-course radiation plus temozolomide in elderly patients with glioblastoma. New Engl J Med. 2017 Mar; 376(11):1027-37. | B | New England Journal of Medicine |
| 01/03/2017 | 8.05 | WBRT | Skin | Hong A; Hallock H; Valenzuela M; Lo S; Paton E; Ng D; Dhillon H; Jacobsen K; Reisse C; Fogarty G. Hippocampal avoidance whole brain radiation therapy is associated with preservation of hippocampal volume at six months: a case series. Neurooncol Open Access 2017 Mar; 1:1. | C | Neuro Oncology Open Access |
| 01/02/2017 | 11.01 | SUPREMO | Breast | Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron D, Bartlett J, Bowman A, Piper T, Cunningham C, Canney P, Kunkler I. The BIG 2.04 MRC/EORTC SUPREMO Trial - Pathology quality assurance of a large phase 3 randomised international clinical trial of post mastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Res Treat. 2017 Feb; 163(1):63-9. | B | Breast Cancer Research and Treatment |
| 01/02/2017 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, House MJ, Kennedy A, Matthews J, Joseph DJ, Denham JW. Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface. Int J Radiat Oncol Biol Phys. 2017 Feb; 97(2):420-6 | A | International Journal of Radiation Oncology Biology Physics |
| 01/12/2016 | 3.04 | RADAR | Genitourinary | Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R. Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. Phys Med. 2016 Dec; 32(12):1690-7 | A | Physics Medica |
| 01/11/2016 | 6.01 | LGG | Central Nervous System | Baumert B, Hegi M, Van Den Bent J, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes A, Kantor G, Taphoorn M, Ben Hassel M, Hartmann C, Ryan G, Capper D, Kros J, Kurscheild S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg J, Feuvret L, Reijneveld J, Chinot O, Gijtenbeek J, Rossiter J, Dif N, Balana C, Barvo-Marques J, Clement P, Marosi C, Tzuk-Shina T, Nordal R, Rees J, Lacombe D, Mason W, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1521-32. | B | Lancet Oncology |
| 01/11/2016 | 6.01 | LGG | Central Nervous System | Reijneveld J, Taphoorn M, Coens C, Bromber J, Mason W, Hoang-Xuan K, Ryan G, Beh Assel M, Enting R, Brandes A, Wick A, CHinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulous V, Gorlia T, Bottomley A, Stupp R, Baumert B. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1533-42. | B | Lancet Oncology |
| 01/10/2016 | 3.04 | RADAR | Genitourinary | Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthew J, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016 Oct; 121(1):98-102. | A | Radiotherapy and Oncology |
| 01/10/2016 | 3.04 | RADAR | Genitourinary | Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct; 11(1):144 | A | Radiation Oncology |
| 01/09/2016 | 13.01 | SAFRON II | Lung | Pham D, Hardcastle N, Foroudi F, Kron T, Bressel M, Hilder B, Chesson B, Oates R, Montgomery R, Ball D, Siva S. A Multidisciplinary Evaluation of a Web-based eLearning Training Programme for SAFRON II (TROG 13.01): A Multicentre Randomised Study of Stereotactic Radiotherapy for Lung Metastases. Clin Oncol. 2016 Sep; 28(9):e101-08. | A | Clinical Oncology |
| 01/09/2016 | 8.04 | PORTEC-3 | Gynaecologic | Jameson M, Mcnamara J, Bailey M, Metcalfe P, Holloway L, Foo K, Do V, Mileshkin L, Creutzberg, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imag Radia Oncol. 2016 Sep; 60(4):554-59 | C | Journal of Medical Imaging and Radiation Oncology |
| 01/08/2016 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Kennedy A, Joseph DJ, Denham JW. Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting. Radiother Oncol. 2016 Aug; 120(2):339-45 | A | Radiotherapy and Oncology |
| 01/07/2016 | 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 Jul; 17(8):1114-26. | C | Lancet Oncology |
| 01/06/2016 | 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, Bassett J, Bowe S, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith R, Spry N, Stockler M, Syme R, Tai K, Turner S. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun; 17(6):727-37. | C | Lancet Oncology |
| 01/05/2016 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, House MJ, Kennedy A, Joseph DJ, Denham JW. Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: A comparison of conventional and machine-learning methods. Med Phys. 2016 May; 43(5):2040 | A | Medical Physics |
| 01/04/2016 | 8.03 | RAVES | Genitourinary | Tesson S, Sundaresan P, Ager B, Butow P, Kneebone A, Costa D, Woo H, Pearse M, Juraskova, Turner S. Knowledge, attitudes and decision-making preferences of men considering participation in the TROG RAVES Prostate Cancer Trial (TROG 08.03). Radiother Oncol.2016 Apr; 119(1):84-90. | A | Radiotherapy and Oncology |
| 01/03/2016 | 1.04 | - | Gastrointestinal | McLachlan S, Fisher R, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland S, McKendrick J, McClure B, Mackay J, Ngan S. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar; 55:15-26. | A | European Journal of Cancer |
| 01/02/2016 | 3.06 | TOAD | Genitourinary | Duchesne G, Haworth A, Bone E, Carter H, Ebert M, Gagliardi F, Gibbs A, Hornby C, Martin A, Sidhom M, Wood M, Jackson M. Testing the Assessment of New Radiation Oncology Technologyand Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques. J Med Imag Radiat Oncol. 2016 Feb; 60(1):129-37. | C | Journal of Medical Imaging and Radiation Oncology |
| 01/12/2015 | 8.03 | RAVES | Genitourinary | Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, Wiltshire K, Haworth K, Fraser-Browne C, Martin J. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. Int J Radiat Oncol Biol Phys. 2015 Dec; 93(5):1045-51. | A | International Journal of Radiation Oncology Biology Physics |
| 01/11/2015 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert M, Bulsara M, House M, Kennedy A, Joseph D, Denham J. Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models. Radiother Oncol. 2015 Nov; 117(2):277-82 | A | Radiotherapy and Oncology |
| 01/10/2015 | 3.04 | RADAR | Genitourinary | Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW. Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 ‘RADAR’ trial clinical data. Pathology. 2015 Oct; 47(6):520–25. | A | Pathology |
| 01/10/2015 | 12.03 | EAT | Head and Neck | Beck A, Baker A, Britton B, Wratten C, Bauer J, Wolfenden L, Carter G. Fidelity considerations in translational research: Eating As Treatment - a stepped wedge, randomised controlled trial of a dietitian delivered behaviour change counselling intervention for head and neck cancer patients undergoing radiotherapy. TRIALS. 2015 Oct; 16:465. | C | Trials |
| 01/09/2015 | 2.01 | - | Skin | Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers MB, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry B, Babington S, Duprat J, Hoekstra H, Thompson J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep; 16(9):1049-60. | A | Lancet Oncology |
| 01/07/2015 | 12.03 | EAT | Head and Neck | Britton B, McCarter K, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McElduff P, Halpin S, Carter G. Eating As Treatment (EAT) study protocol: a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy. BMJ Open. 2015 Jul; 5(7):e008921. | C | BMJ Open |
| 01/07/2015 | 3.05 | MA.20 | Breast | Whelan T.J, Olivotto I, Parulekar W, Ackerman I, Chua B, Nabid A, Vallis K, White J, Rousseau P, Fortin A, Pierce L, Manchul L, Chafe S, Nolan M, Craighead P, Bowen J, McCready D, Pritchard K, Gelmon K, Murray Y, Chapman J, Chen B, Levine, M. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015 Jul; 373(4):307-16. | B | New England Journal of Medicine |
| 01/07/2015 | 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW. Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol. 2015 July; 116(1):112-8, | A | Radiotherapy and Oncology |
| 01/06/2015 | 11. A | ANROTAT | NA | Duchesne G, Grand M, Kron T, Haworth A, Corry J, Jackson M, Burmeister B. (2014). Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. J Med Imag Radiat Oncol. 2015 Jun; 59(3):363-70. | A | Journal of Medical Imaging and Radiation Oncology |
| 01/06/2015 | 11. A | ANROTAT | NA | Brown E, Cray A, Haworth A, Chander S, Lin R, Subramanian B, Ng M. Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Rad Sci. 2015 Jun; 62(2):99-107. | A | Journal of Medical Radiation Sciences |
| 01/06/2015 | 3.04 | RADAR | Genitourinary | Denham J, Steigler A , Joseph D, Lamb D, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna N, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday E, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol. 2015 Jun; 115(3):301-07. | A | Radiotherapy and Oncology |